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  14 
Abstract 15 
Purpose In this work, the identification and characterization of the novel synthetic 16 
cathinone 5-PPDI found in a suspect drug sample was performed. 17 
Methods The suspect sample was analyzed by gas chromatography–mass spectrometry 18 
(GC–MS), Fourier-transformed infrared spectroscopy (FTIR), ultra-high performance 19 
liquid chromatography–high-resolution mass spectrometry (UHPLC–HRMS) and 20 
nuclear magnetic resonance (NMR). 21 
Results The fragmentation observed in GC–MS and the identification of functional 22 
groups by FTIR were not enough for compound identification. After an exhaustive 23 
analysis of the accurate-mass fragmentation observed in HRMS, the compound was 24 
tentatively identified as the novel cathinone 5-PPDI. Finally, five different NMR 25 
experiments were used for the unequivocal identification and complete characterization 26 
of the compound. In addition, the origin of this cathinone was investigated in depth. 27 
Conclusions The analytical data provided in this work will be useful for the 28 
identification of 5-PPDI by forensic laboratories. In addition, the origin of this 29 
cathinone has been investigated, which could be of interest for the identification of 30 
future synthetic cathinones prepared following the same synthesis route than that 31 
employed for obtaining 5-PPDI. 32 
 33 
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Introduction 37 
According to the last report from the European Monitoring Centre for Drug and 38 
Drug Addiction (EMCDDA), 14 novel cathinones were reported in the European Union 39 
in 2016. Synthetic cathinones represent the second largest novel psychoactive substances 40 
(NPS) family, with 118 compounds currently being monitored by EMCDDA. These 41 
compounds were the most commonly seized NPS in 2015, representing the third part of 42 
the total number of seizures [1]. Of these, many are pyrovalerone analogs; they are 43 
cathinones that contain the pyrrolidine moiety (42 substances) [1]. The compound 44 
reported in this paper, 5-PPDI, newly appeared as a new pyrovalerone analog that 45 
produces effects in humans and is not controlled. It is the indane analog of α-PBP, a drug 46 
that is currently controlled in the USA, China, and other countries [2, 3]. It is likely that 47 
it shares the same synthetic route, albeit with different precursors, as other pyrovalerone 48 
derivatives (α-bromination of the pentan-1-one precursor to form the 2-bromopentan-1-49 
one intermediate, and reaction with pyrrolidine to yield the substance), and therefore the 50 
synthesis is easy to carry out by a facility that has the means to manufacture α-PBP [4]. 51 
Monitoring and identification of NPS is still handicaped due to this wide range of 52 
structures along with their high turn-out rate. For this reason, it is essential to keep 53 
developing analytical approaches for their characterization [5–7]. 54 
The most commonly used analytical techniques in toxicological routine 55 
laboratories are Fourier-transformed infrared (FTIR) spectroscopy and gas 56 
chromatography–mass spectrometry (GC–MS), with the predominating ionization source 57 
being electron ionization (EI) [8]. FTIR is especially useful for NPS analysis when 58 
attenuated total reflectance (ATR) is used, allowing a direct analysis with a small amount 59 
of recoverable sample. The use of ATR-FTIR has recently demonstrated its potential for 60 
direct classification of NPS in seizures through the use of multivariate discriminant 61 
analysis, allowing compound identification with a cost-effective and rapid analysis (2 min 62 
per sample) [9, 10]. Nevertheless, this methodology can only be applied if the compound 63 
spectrum has been previously acquired, which limits its suitability for monitoring 64 
emerging NPS. GC-MS is probably the most frequently used instrumental technique in 65 
the field of toxicology, where its applicability for cathinone analysis has been widely 66 
reported [11–14]. Although GC–MS provides a way to quickly identify a compound by 67 
the use of EI spectrum libraries, the frequent emergence of novel cathinone derivatives 68 
proves a serious drawback. First of all, most of the novel cathinones that have been 69 
detected recently are not listed in spectral libraries. Additionally, these cathinone 70 
derivatives tend to produce very similar (or identical) fragmentation patterns, and the 71 
identification of the molecular ion is commonly difficult due to the high fragmentation 72 
produced by an EI source [13].  73 
Recent studies dealing with the analysis of synthetic cathinones have been carried 74 
out by ultra-high performance liquid chromatography (UHPLC) coupled to high 75 
resolution mass spectrometry (HRMS), using electrospray ionization (ESI) interface as 76 
the ionization source. These studies have demonstrated the potential of this technique for 77 
cathinone identification in legal high samples, usually employing a hybrid quadrupole 78 
time-of-flight (QTOF) mass analyzer [15, 16]. The QTOF instrument allows for a 79 
tentative compound identification even without the use of reference standards. Moreover, 80 
the applicability of the “non-target” approach for unknown compounds present in these 81 
samples has also been demonstrated [17]. 82 
When no reference standard is available, the use of UHPLC–HRMS is not enough 83 
for compound identification, and thus, additional spectroscopic techniques must be used. 84 
Nuclear magnetic resonance (NMR) is one of the most useful techniques for structural 85 
elucidation (including synthetic cathinones), allowing the differentiation of the 86 
substitutional isomerism without the use of reference standards [18–20]. Thus, the 87 
combination of UHPLC–HRMS and NMR allows the identification and complete 88 
characterization of unknown (or unreported) NPS [17, 21–24]. 89 
In this work, an unknown white powder (suspected to contain a synthetic 90 
cathinone) was received in our laboratory. After analysis by GC–MS and ATR-FTIR, the 91 
compound could not be identified. Analysis by UHPLC-HRMS allowed a tentative 92 
compound identification of the unreported synthetic cathinone 1-(2,3-dihydro-1H-inden-93 
5-yl)-2-(pyrrolidin-1-yl)butan-1-one, sold in several webpages as 5-PPDI. The analysis 94 
of this cathinone by NMR in combination with HRMS data provided enough information 95 
for the unequivocal compound identification. 96 
 97 
Materials and methods 98 
Drug sample 99 
The suspect sample was submitted by an anonymous user to Energy Control’s 100 
drop-in service for its analysis. Additional information about Energy Control can be seen 101 
elsewhere [25]. 102 
 103 
Reagents and chemicals  104 
For GC–MS analysis, GC-grade n-hexane and GC-grade acetone were purchased 105 
from Scharlau (Scharlab, Barcelona, Spain). For UHPLC-HRMS analysis, HPLC-grade 106 
water was obtained by purifying demineralized water using a Milli-Q system from 107 
Millipore (Bedford, MA, USA). HPLC-grade methanol, HPLC-grade acetonitrile, formic 108 
acid, acetone, and sodium hydroxide (NaOH) were acquired from Scharlau. Leucine 109 
enkephalin was purchased from Sigma-Aldrich (St. Louis, MO, USA). For NMR 110 
analysis, deuterated chloroform (CDCl3) was purchased from Sigma-Aldrich. For FTIR 111 
analysis potassium bromide (KBr) was purchased from Scharlau. 112 
 113 
Sample treatment 114 
For FTIR analysis, the sample was directly analyzed by ATR-FTIR spectroscopy. 115 
For GC-MS analysis, 10 mg of sample were extracted with 1 mL of acetone in an 116 
ultrasonic bath for 15 min. After centrifugation, the supernatant was five thousand-fold 117 
diluted with GC-grade n-hexane, and 1 µL of the extract were injected in the GC-MS 118 
system.  119 
For UHPLC-HRMS analysis, 10 mg of sample were extracted with 1 mL of 120 
acetone in an ultrasonic bath for 15 min. After centrifugation, the supernatant was ten 121 
thousand-fold diluted with HPLC-grade water, and 20 µL of the extract were injected in 122 
the UHPLC-HRMS system.  123 




For FTIR analysis, a Jasco FT/IR-6200 FTIR spectrometer (Jasco Inc., Easton, 128 
MD, USA) equipped with a Specac Silver Gate ATR accessory (Specac, Orpington, UK) 129 
was used. Data acquisition was performed at 23 ºC between 4000 and 400 cm-1, with a 130 
resolution of 4 cm-1 and performing 32 acquisitions. 131 
For GC–MS analysis, an Agilent 6890N gas chromatograph (Agilent 132 
Technologies, Santa Clara, CA, USA) equipped with an Agilent 7683 autosampler 133 
(Agilent Technologies) was coupled to a Quattro Micro GC triple quadrupole mass 134 
spectrometer (Micromass, Boston, MA, USA)  using an electron ionization (EI) interface. 135 
The injector and the interface were operated at 250 ºC. A 1-µL aliquot of sample was 136 
injected in splitless mode using deactivated liners into a 30 m x 0.25 mm i.d., 0.25 μm 137 
film thickness DB-5MS column (Agilent Technologies). Helium (99.999%; Praxair, 138 
Valencia, Spain) was used as carrier gas at a flow rate of 1 mL/min. The oven temperature 139 
was initially maintained at 90 ºC for 1 min and programmed to reach 300 ºC at 20 ºC/min. 140 
It was finally maintained at 300 ºC for 1.5 min (total run time was 12 min). The mass 141 
spectrometer was operated in electronic ionization mode at 70 eV. MS system worked in 142 
scan acquisition mode, acquiring from m/z 50 to 400 Da. Analytical data were acquired 143 
and processed using MassLynx data station operation software (version 4.0; Waters, 144 
Mildford, MA, USA). 145 
UHPLC–HRMS analysis was performed using an ACQUITY UHPLC system 146 
(Waters) coupled to a XEVO G2 QTOF hybrid QTOF mass spectrometer (Waters 147 
Micromass, Manchester, UK) with an orthogonal Z-spray ESI interface operating in 148 
positive ionization mode. The chromatographic separation was performed using a 149 
CORTECS C18 (Waters) analytical column (100 x 2.1 mm i.d., 2.7 µm particle size; 150 
Waters) at a flow rate of 0.3 mL/min. The column temperature was set to 40 ºC. The 151 
mobile phases used were H2O with 0.01% formic acid (A) and methanol with 0.01% 152 
formic acid (B). The mobile phase gradient was performed as follows: 10% of B at 0 min, 153 
90% B at 14 min linearly increased, 90% B at 16 min, and finally 10% B at 18 min in 154 
order to return to initial conditions. The injection volume was 20 µL. Nitrogen (Praxair) 155 
was used as desolvation and nebulizing gas. The desolvation gas flow was set at 1000 156 
L/h. The TOF resolution was ~20000 at full width at half maximum at m/z 556. The range 157 
acquired by the MS system was m/z 50 to 1000. A capillary voltage of 0.7 kV and a cone 158 
voltage of 20 V were used during all the chromatographic run. Argon 99.995% (Praxair) 159 
was used as a collision gas. The interface temperature was set to 650 ºC and the source 160 
temperature to 120 ºC. For MSE experiments, two acquisition functions with different 161 
collision energy were created. The low energy function used a collision energy of 4 eV 162 
in order to obtain information about the protonated molecule and adducts (if present), 163 
while the high energy function applied a collision energy ramp from 15 to 40 eV, in order 164 
to promote fragmentation of the compounds. Calibration of the mass-axis was performed 165 
daily from m/z 50 to 1000 using 0.05 M NaOH/5% formic acid (1:1, v/v), diluted 25-fold 166 
with acetonitrile/H2O  mixture (80:20, v/v). For accurate mass measurement, a 2 µg/mL 167 
leucine enkephalin solution in acetonitrile/H2O  with 0.1% formic acid (50:50, v/v) was 168 
used as lock-mass, and pumped at a flow rate of 20 µL/min. The leucine enkephalin 169 
protonated molecule (m/z 556.2771) was used for recalibrating the mass axis and ensure 170 
an accurate mass during all the chromatographic run. UHPLC-HRMS data were acquired 171 
in continuum mode using MassLynx data station operation software (version 4.1; Waters) 172 
and processed with UNIFI scientific information system (version 1.8; Waters). 173 
NMR analyses were performed using a Bruker Ascend 400 MHz spectrometer 174 
equipped with a SampleCase autosampler (Bruker, Etlingen, Germany), performing data 175 
acquisition at 303 K using CDCl3. The residual solvents signals at δ = 7.24 ppm for 
1H 176 
(CHCl3) and at δ = 77.23 ppm for 
13C (CDCl3) were used as internal references. 177 
Characterization of the compound was performed using 5 gradient-enhanced 178 
experiments: 1H NMR, 13C NMR, correlated spectroscopy (COSY), heteronuclear single 179 
quantum coherence (HSQC) and heteronuclear multiple bond correlation (HMBC). NMR 180 
experiment data were collected using the Bruker Icon NMR 5.0.5 software (Bruker). 181 
MestreNova program was used for raw data processing (Mestrelab Research, Santiago de 182 
Compostela, Spain). 183 
 184 
Results and discussion 185 
Infrared spectroscopy and gas chromatography –mass spectrometry 186 
Preliminary analyses were performed by ATR-FTIR and GC–MS. In the case of 187 
FTIR analysis, no spectra databases were available at our laboratory, and therefore only 188 
functional groups could be identified. No significant information could be obtained, and 189 
only aliphatic (<3000 cm-1) and aromatic (>3000 cm-1) C-H stretching signals, and 190 
carbonyl stretching signal (1675 cm-1) were present in the FTIR spectrum. The FTIR 191 
spectrum and the identification of the observed bands can be found in supplementary 192 
material Fig. S1. 193 
Analysis by GC–MS revealed the presence of only one organic compound, 194 
detectable by this equipment, which presented a chromatographic peak at 9.45 min. When 195 
the mass spectrum of this chromatographic peak was extracted (Fig. 1), no matches were 196 
obtained after applying the spectra libraries available at the laboratory (NIST, Cayman 197 
Chemical, and a home-made library). The fragmentation spectrum showed only an 198 
intense fragment ion at m/z 112. No information about the molecular ion could be 199 
obtained from the EI spectrum. 200 
The combination of the information provided by FTIR and GC–MS was not 201 
enough for compound identification, requiring analysis by HRMS (and NMR) for 202 
compound identification. 203 
 204 
High-resolution mass spectrometry 205 
The analysis by UHPLC–HRMS confirmed the high purity of the sample, and only a 206 
chromatographic peak was observed in the total ion current chromatogram. The low 207 
energy function spectrum of this chromatographic peak showed an ion at m/z 258.1845, 208 
corresponding to the protonated molecule of the compound (C17H24NO
+, -2.9 ppm) (Fig. 209 
2a). The fragmentation observed in the high energy function spectrum suggested the 210 
compound to be a synthetic cathinone (Fig. 2b). The product ion 2 observed at m/z 211 
187.1111 (C13H15O
+, -3.4 ppm) suggested the presence of a pyrrolidine moiety (neutral 212 
loss of C4H9N, 71.0735 Da). This neutral loss has been described for several synthetic 213 
cathinones with a pyrrolidine moiety [15, 20, 22, 23]. The product ion 4(at m/z 145.0642, 214 
C10H9O
+, -4.5 ppm) indicated that the alkyl chain in the α-carbon of the cathinone should 215 
be an ethyl moiety. This fact was in accordance to product ion 1at m/z 229.1448 216 
(C15H19NO
+·, -5.8 ppm), corresponding to a radical loss of 29.0391 Da (C2H5
·). Finally, 217 
product ion 6 at m/z 117.0692 (C9H9
+, -5.8 ppm) was obtained after a CO loss (27.9949 218 
Da) from product ion 4. The double bond equivalence for product ion 6 indicated the 219 
presence of 5 insaturations, 4 of them corresponding to the aromatic ring. The remaining 220 
one, and the presence of 3 carbon atoms, could be related with the presence of a 2,3-221 
dihydroindene moiety. 222 
Thus, a pyrrolidine, an ethyl and a 2,3-dihydroindene moieties would be the three 223 
parts of the cathinone structure, being proposed as 1-(2,3-dihydro-1H-inden-5-yl)-2-224 
(pyrrolidin-1-yl)butan-1-one. Searching for this systematic name on different websites 225 
which sell research chemicals, our putative cathinone was found under the name of 5-226 
PPDI. To the best of our knowledge, this synthetic cathinone has not been reported yet. 227 
Once the compound was tentatively identified as 5-PPDI, the fragmentation pathways for 228 
this synthetic cathinone were proposed. As it is shown in Fig. 3, all the observed product 229 
ions could be justified based on the structure of this cathinone. The base peak at m/z 112 230 
observed in the EI mass spectrum (Fig. 1) corresponds to the product ion 7. 231 
Nevertheless, the information obtained by HRMS allowed only a tentative 232 
identification. The complete characterization and unequivocal identification of the 233 
compound was performed by the combination of different NMR experiments. 234 
 235 
Nuclear magnetic resonance 236 
Fig. 4 shows the 1H NMR spectrum and the 13C NMR spectrum for the tentatively 237 
identified 5-PPDI, and Table 1 presents signal assignment for 1H and 13C NMR signals. 238 
For 1H NMR spectrum, all the observed signals could be justified based on the 239 
structure of 5-PPDI without major problems. Nevertheless, some signals presented certain 240 
curiosities that should be discussed in more detail. Resonances of hydrogen atoms 4 and 241 
5 presented broad signals, as usual in aliphatic rings with heteroatoms (for example, the 242 
pyrrolidine moiety) [20, 22, 23]. Methylene hydrogens signals which present resonance 243 
between δ 1.75 and 2.25 presented overlapping, making the assignation of these signals 244 
difficult. These signals were finally assigned after an accurate evaluation of the COSY 245 
and HSQC spectra, which can be found in supplementary material (Fig. S2). The study 246 
of HSQC spectra also allowed a direct assignation of 13C NMR signals. 247 
The combination of the NMR experiments and the fragmentation observed in 248 
HRMS, allowed the complete characterization of the compound and thus, its 249 
identification. Nevertheless, in order to enhance the confidence of compound structure, 250 
an additional bidimensional NMR experiment was performed. Fig. 5 shows the HMBC 251 
spectrum of 5-PPDI. The multiple bond correlations observed in this experiment 252 
confirmed the structure initially proposed. Thus, the compound was unequivocally 253 
identified as the synthetic cathinone 5-PPDI. 254 
 255 
Reasons behind synthesizing 5-PPDI 256 
Structure-activity relationship (SAR) is very difficult to deduce from theoretical 257 
data. There is some available information on the SAR of amphetamines, but less for the 258 
SAR of synthetic cathinones. 259 
Although SARs of amphetamines and synthetic are not the same, some inferences 260 
can be made from modifications in one family to the other. It has been shown that the 261 
phenyl ring in pyrovalerone derivatives can be substituted with a benzodioxole and the 262 
compound will retain similar activity (α-PVP to MDPV, Fig. 6). Similarly, the 263 
benzodioxole moiety in MDA can be substituted with an indane and also will retain 264 
similar properties (MDA to 5-APDI). It is therefore a reasonable assumption that the 265 
benzodioxole and phenyl moieties are interchangeable in pyrovalerone derivatives and 266 
amphetamine analogs. Then, the benzodioxole could be replaced by an indane, 267 
substituting the phenyl moiety of α-PBP with an indane moiety which will yield to the 268 
active compound 5-PPDI. Replacing the phenyl moiety of α-PBP with a benzodioxole 269 
leads to MDPBP, a compound that is, at least, active; it is a logical next step to see if 270 
something similar happens with 5-PPDI (Fig. 6). 271 
Because 5-PPDI has not previously appeared in the literature and little is known 272 
about it, vendors tend to send it for free with other orders, or even to send a sample at no 273 
cost to the consumer in an attempt to get users to describe its effects and generate interest 274 
in the substance [26]. It appears that the compound is inactive at dosages similar to other 275 
pyrovalerone derivatives, and users tend to not push the dose above which they perceive 276 
as safe. Some users report light activity, especially with administration through 277 
vaporization of the compound, which is reported to be more potent than oral or nasal use. 278 
Reports are mixed however, likely due to factors such as purity, personal tolerance, route 279 
of administration, etc., leading to conflicting reports such as one user reporting 20 mg 280 
vaporized to be an active dose, and another reporting that 32 mg vaporized to yield no 281 
effects. It is also possible that some vendors claim to ship 5-PPDI, but in reality they ship 282 




This work presents the detection and characterization of the novel cathinone 1-287 
(2,3-dihydro-1H-inden-5-yl)-2-(pyrrolidin-1-yl)butan-1-one, better known as 5-PPDI. 288 
The results obtained in this study remark the limitations of the routine analysis techniques 289 
used in forensic laboratories for NPS detection and identification. Thus, FTIR 290 
spectroscopy and GC–MS allow a rapid identification of the sample only if the 291 
corresponding spectrum has been previously recorded.  292 
In this work, GC–MS revealed that the compound was highly pure, without any 293 
other organic compound being detected. Nevertheless, no matches were obtained for the 294 
acquired spectrum using commercial libraries, illustrating that this technique is not 295 
efficient for structure elucidation of unknown substances or unanalyzed compounds; 296 
therefore, advanced techniques are required for that aim. 297 
The analysis by UHPLC–HRMS allowed a tentative identification of the 298 
compound, based on the accurate-mass fragmentation observed. Nevertheless, due to the 299 
lack of an analytical reference standard at the moment of developing this work, the 300 
compound could not be unequivocally identified based only on HRMS data. The use of 301 
different NMR experiments (1H, 13C, COSY, HSQC and HMBC) confirmed its structure, 302 
and after combining this information with that obtained by HRMS, the substance was 303 
unequivocally characterized as 5-PPDI. 304 
The analytical data provided in this work will facilitate the detection and 305 
identification of this novel synthetic cathinone by forensic and toxicological laboratories, 306 
even if they use routine techniques.  307 
Although this compound does not appear to be very potent, and it will be unlikely 308 
to see its widespread use, it is interesting to consider that it was synthesized with a clear 309 
objective to produce a viable alternative to compounds like α-PBP. Its structure 310 
demonstrates some knowledge on pharmacology and SAR of synthetic cathinones, and 311 
contributes to clarifying the theory, by which manufacturers of NPS are proficient at 312 
finding alternatives to banned compounds. Such a theory casts a doubt on the efficacy of 313 
systematically scheduling NPS, because manufacturers have been able to provide 314 
alternatives that not only evade legislation, but also are usually active compounds. 315 
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Fig. 1 Electron ionization mass spectrum of a chromatographic peak at 9.54 min, 445 
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Fig. 2 MSE spectra of the unknown compound. Low energy function (a) and high 452 
energy function (b) spectra of the tentatively identified 5-PPDI 453 








































Fig. 3 Proposed collision induced dissociation (CID) fragmentation pathways for the 5-456 
PPDI 457 
  458 
 459 
Fig. 4 Nuclear magnetic resonance spectra of the unknown substance. a 1H spectrum, 460 
with proton-signal assignation based on the structure of 5-PPDI. b 13C spectrum, with 461 
carbon-signal assignation based on its structure 462 

























































Fig. 5 Heteronuclear multiple bond correlation (HMBC) spectra of the compound 465 
identified as 5-PPDI 466 






































Fig. 6 Structures of synthetic cathinones with moiety changes to 5-PPDI 469 




Table 1 1H and 13C nuclear magnetic resonance signal assignment 471 
1H NMR signal assignment  13C NMR signal assignment 
Hydrogen δ (ppm) Multiplicity  Carbon δ (ppm) 
1 0.94 triplet  1 10.88 
2 2.08, 2.29 multiplet  2 25.27 




a  4 48.72, 52.88 
5 1.93, 2.08 a  5 23.92 
6 - -  6 196.43 
7 - -  7 153.16 
8 7.74 singlet  8 124.39 
9 - -  9 145.93 
10 2.92 triplet  10 32.52, 33.21 
11 2.08 a  11 24.44 
12 - -  12 134.62 
13 7.31 doublet  13 125.21 
14 7.67 doublet  14 127.20 
 
δ chemical shift. 472 
a multiplicity of these signals could not be stablished 473 
 474 
 475 















Fig. S1 FTIR spectrum of the unknown compound. Characteristic bands are highlighted 478 





































Fig. S2 a COSY spectrum of 5-PPDI, showing the correlation between hydrogens. b 482 
HSQC spectrum of 5-PPDI, linking 1H and 13C NMR signals. CH3 and CH groups are 483 
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